Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Company Drug

BMS Reports Positive POETYK PsA-1 Results for Sotyktu in Psoriatic Arthritis

Fineline Cube Jun 13, 2025

US-based Bristol-Myers Squibb (BMS; NYSE: BMY) announced positive results from the pivotal Phase III POETYK...

Company Drug

Lilly Launches Mounjaro Multi-Dose Pen in China for Diabetes and Weight Management

Fineline Cube Jun 13, 2025

US-based Eli Lilly & Co. (NYSE: LLY) announced the launch of Mounjaro (tirzepatide multi-dose prefilled...

Company Deals

XtalPi Acquires Liverpool ChiroChem to Boost AI-Driven Drug Discovery

Fineline Cube Jun 12, 2025

Shenzhen-based XtalPi Holdings Limited (HKG: 2228), an AI-driven pharmaceutical company, announced the complete acquisition of...

Company Deals

Shandong Boan Partners with Shanghai Pharma for BA5101 Diabetes Drug

Fineline Cube Jun 12, 2025

China-based Shandong Boan Biotechnology Co., Ltd (HKG: 6955) announced a strategic collaboration with Shanghai Pharmaceuticals...

Company Deals

GCCF and CTTQ Explore Collaboration to Expand Innovative Drug Access in Hong Kong

Fineline Cube Jun 12, 2025

Dr. Cheng Kam-chung, Founder and Chairman of the Greater China Cancer Foundation (GCCF), led a...

Company Drug

ImmVira Commences Phase II Trial for MVR-T3011 in High-Risk NMIBC

Fineline Cube Jun 12, 2025

Shenzhen-based ImmVira announced that it has administered the first patient dose in a global, multi-center...

Company Deals

Escugen Partners with SovranBio to Accelerate Development of Antibody-Drug Conjugates

Fineline Cube Jun 12, 2025

Shanghai Escugen, a China-based clinical-stage company specializing in innovative antibody-drug conjugate (ADC) development, announced a...

Company Medical Device

Varian Medical Systems Secures NMPA Approval for Ethos 2.0 AI Radiotherapy Platform

Fineline Cube Jun 12, 2025

US-based Varian Medical Systems (NYSE: VAR) announced that it has received marketing approval from China’s...

Company

Novo Nordisk China Restructures to Form New Obesity and Diabetes Department

Fineline Cube Jun 12, 2025

Danish pharmaceutical giant Novo Nordisk’s (NYSE: NVO) China unit announced an organizational restructuring, merging its...

Company Deals

Eli Lilly Partners with Juvena Therapeutics on Muscle Health AI Platform

Fineline Cube Jun 12, 2025

US-based Eli Lilly & Co. (NYSE: LLY) announced a global licensing and multi-target research collaboration...

Company Drug

Daiichi Sankyo Launches Phase I Trial for Enhertu Subcutaneous Formulation

Fineline Cube Jun 12, 2025

Japan-based Daiichi Sankyo (TYO: 4568) has registered a Phase I clinical trial on ClinicalTrials.gov for...

Medical Device Policy / Regulatory

NMPA Issues Immediate Guidelines for NGS-Related IVD Reagent Classification

Fineline Cube Jun 12, 2025

China’s National Medical Products Administration (NMPA) released the “Guidelines for Classification Definition of Next-Generation Sequencing...

Policy / Regulatory

China Updates Class 3 Hospital Accreditation Standards for 2025

Fineline Cube Jun 12, 2025

Last month, China’s National Health Commission officially issued the Class 3 Hospital Accreditation Standards (2025...

Company Drug

Huadong Medicine Receives NMPA Approval for Phase III Trial of Roflumilast Foam

Fineline Cube Jun 11, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that Its wholly-owned subsidiary Hangzhou Zhongmei Huadong...

Company Drug

China’s Sichuan Kelun-Biotech Wins BTD for Sac-TMT in Non-Squamous NSCLC

Fineline Cube Jun 11, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that its core product Jiatailai (sacituzumab...

Policy / Regulatory

China’s CDE Seeks Feedback on Advanced Therapy Medicinal Products Guidelines

Fineline Cube Jun 11, 2025

China’s Center for Drug Evaluation (CDE) released a draft guideline titled “Scope, Classification and Definitions...

Company Deals

Philochem Grants RayzeBio Global Rights to OncoACP3 for Prostate Cancer

Fineline Cube Jun 11, 2025

Switzerland-based Philochem AG, a wholly-owned subsidiary of the Philogen Group (BIT: PHIL), announced a licensing...

Company Drug

Henlius Biotech Starts Global Phase II Trial for PD-L1 ADC HLX43

Fineline Cube Jun 11, 2025

China’s Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing in a global,...

Company Deals Medical Device

Tawada Healthcare Secures Series A+ Funding Led by Highlight Capital

Fineline Cube Jun 11, 2025

Indonesian integrated medical equipment service provider Tawada Healthcare (THC) has reportedly raised “tens of millions”...

Company Drug

Merck’s Pimicotinib NDA Accepted for Review by China’s CDE

Fineline Cube Jun 11, 2025

German pharmaceutical major Merck KGaA (ETR: MRK) announced that the New Drug Application (NDA) for...

Posts pagination

1 … 172 173 174 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.